Sat, May 18, 2013, 8:24 PM EDT - U.S. Markets closed
Announces Initiation of Phase II Trial of ADCETRIS® as Front-line Therapy for Hodgk. It is rated a strong buy at stoxline website with the 34.84 target price in six months.